Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates


Neutropenia and thrombocytopenia: 16 case reports

    • 10 Accesses

    This is a preview of subscription content, log in to check access.


    1. 1.

      Palma MD, Lombardi G, Donach ME, Borgato L, Zustovich F, Furini L, Nicoletto MO.Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment. American Journal of Clinical Oncology 34: 305-308, No. 3, Jun 2011. Available from: URL: http://dx.doi.org/10.1097/coc.0b013e3181e1cb22 - Italy

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Carboplatin/paclitaxel. React. Wkly. 1361, 14 (2011). https://doi.org/10.2165/00128415-201113610-00047

    Download citation


    • Ovarian Cancer
    • Neuropathy
    • Paclitaxel
    • Doxorubicin
    • Tamoxifen